Reach Us +44-1647-403003
The Ginger Product 6-shogaol Shows Promise In Breast Cancer Treatment By Inhibiting Breast Cancer Cells And Stem Cell Like Spheroids | 53462
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

The ginger product 6-shogaol shows promise in breast cancer treatment by inhibiting breast cancer cells and stem cell like spheroids

3rd World Congress on Women’s Health & Breast Cancer

Suparna Sengupta

Rajiv Gandhi Centre for Biotechnology, India

ScientificTracks Abstracts: J Cancer Sci Ther

DOI: 10.4172/1948-5956.C1.087

Breast cancer therapy suffers serious obstacle for the presence of cancer stem cells in tumors as they can be responsible for poor prognosis and tumor relapse. Very few chemotherapeutic compounds shows promise to kill these cells. Dietary compounds are welcome options for human diseases due to their time-tested acceptability by human bodies. The gingerderived compound 6-shogaol was effective in killing both breast cancer monolayer cells and cancer-stem cell-like spheroids at doses that were not toxic to noncancerous cells. Both hormone responsive and triple negative breast cancer cells were sensitive to the lethal action of 6-shogaol. 6-shogaol treatment induced autophagy in both monolayer and spheroid culture. Kinetic analysis revealed that the autophagic flux instigated cell death in 6-shogaol treated breast cancer cells. Very low level of apoptosis induction and drastic reduction of cell death by the inhibition of autophagy suggested that autophagy was the major mode of cell death induced by 6-shogaol in breast cancer cells. 6-shogaol reduced the expression levels of cleaved Notch1 and its target proteins Hes1 and cyclin D1 in spheroids, and the reduction was further pronounced in presence of a γ-secretase inhibitor. Secondary sphere formation in presence of the inhibitor was also further reduced by 6-shogaol. Together, these results indicate that the inhibitory action of 6-shogaol on spheroid growth and sustainability is conferred through γ-secretase mediated down-regulation of Notch signaling. The efficacy of 6-shogaol in monolayer and cancer stem cell-like spheroids raise hope for its therapeutic benefit in breast cancer treatment.

Suparna Sengupta has completed her PhD from Bose Institute, India and Post-doctoral research from University of Kansas, USA. Currently, she is a Senior Scientist in Rajiv Gandhi Centre for Biotechnology, India and her research interest includes “The role of cytoskeletal proteins on mitosis, apoptosis and drug development”. She has published several papers in high impact journals and acted as reviewer in many national and international journals. Her awards include Indian Association for Cancer Research Award, National Woman Bio Scientist Award from Government of India. She is a Fellow of International Union against Cancer.

Email: [email protected]

Relevant Topics